SOPHiA GENETICS (NASDAQ:SOPH) Chairman Sells $132,600.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 20,000 shares of the stock in a transaction on Tuesday, July 21st. The shares were sold at an average price of $6.63, for a total value of $132,600.00. Following the completion of the transaction, the chairman owned 3,492,822 shares of the company’s stock, valued at $23,157,409.86. This trade represents a 0.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Monday, July 20th, Jurgi Camblong sold 24,381 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.29, for a total value of $153,356.49.
• On Friday, July 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.62, for a total transaction of $47,770.00.
• On Tuesday, July 7th, Jurgi Camblong sold 17,685 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.28, for a total transaction of $93,376.80.
• On Monday, July 6th, Jurgi Camblong sold 22,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.25, for a total transaction of $118,051.50.
• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total transaction of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.80, for a total transaction of $290,400.20.
• On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.24, for a total transaction of $44,540.00.

SOPHiA GENETICS Trading Up 3.8%

SOPHiA GENETICS stock opened at $5.76 on Friday. The company has a 50 day moving average price of $5.45 and a 200 day moving average price of $5.09. SOPHiA GENETICS SA has a 52 week low of $2.92 and a 52 week high of $6.77. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06. The firm has a market capitalization of $483.21 million, a price-to-earnings ratio of -11.08 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The firm had revenue of $21.69 million for the quarter, compared to analyst estimates of $20.40 million. SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. Research analysts forecast that SOPHiA GENETICS SA will post -0.58 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on SOPH. HC Wainwright began coverage on SOPHiA GENETICS in a research report on Monday, July 20th. They set a “buy” rating and a $12.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Finally, BTIG Research reiterated a “buy” rating and issued a $8.00 target price on shares of SOPHiA GENETICS in a report on Monday, June 15th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $9.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after purchasing an additional 5,432,871 shares in the last quarter. Akre Capital Management LLC grew its stake in shares of SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after buying an additional 1,481,636 shares in the last quarter. Hodges Capital Management Inc. bought a new stake in shares of SOPHiA GENETICS in the 1st quarter valued at approximately $2,157,000. Royce & Associates LP acquired a new position in SOPHiA GENETICS in the fourth quarter worth approximately $2,009,000. Finally, Sei Investments Co. acquired a new position in SOPHiA GENETICS in the first quarter worth approximately $1,772,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.